FGFR4 and hepatocellular carcinoma: Given the important role of this receptor family in the development and progression of HCC, several inhibitors of the FGF/FGFR signaling pathway have been developed over the years, from the early multi-target pan-FGFR to the more recent selective FGFR4 inhibitors currently in Phase I/II clinical trials (NCT04194801 and NCT02508467, respectively).